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Introduction
There has been a considerable interest in the use of SOD in medicine over the last years arising from its ability to reduce deleterious effects of 0 2~ in the cells. These radicals as well as H 20 2 and the hydroxyl radicals are continuously generated in all aerobic organisms. They can cause widespread damage to the cell affecting nucleic acids, proteins and lipids (Sies, 1993) . In addition to their genera tion, reactive oxygen radical (ROS) formation ap pears to be markedly increased during stress con ditions. Oxidative stress is strongly implicated in more than 50 hum an diseases including cancer (Okada et al., 1999; Seidman et al., 1999; Weber and Bruch, 1999) . During the last years, clinical investigations have indicated that oxidant-antioxidant balance is changeable during the oncogenic process. Several authors have dem onstrated that antioxidant levels in more human and animal can cers are low Janssen et al., 1999; Ambrosone et al., 1999; Bittinger et al., 1998; Grammatico et al., 1998) . Zhong et al. (1997) found a suppression of the malignant phenotype of human glyoma cells by overexpression of MnSOD. Kiningham et al. (1997) supposed that MnSOD is a new type of a suppressor of tum or genes, and overexpression of this enzyme selec-tively modulates the activity of some transcription factors in fibrosarcoma cells. However, in some cancer types elevated levels of antioxidant en zymes have been found, particularly SOD (Arivazhagan et al., Jung et al., 1997; Kahlos et al., 1999) . Animal experiments have supported the concept that SOD has a protective effect during the prom otional phases of cancer development. Recently, Li et al. (1998) established a protective action of several antioxidants on the tumor trans formation. both, in vivo and in vitro. Inoculation of Cu/ZnSOD was shown to prolong the survival of experim ental animals with Ehrlich ascites and Sarcoma 180 tumors (Oberley and Buetner, 1979) .
Materials and Methods

Tumor
The myeloid tumor, induced by Graffi virus, was adapted to hamsters (Jakimov et al., 1979) . The tum or was initiated in the Institute of Experim en tal Pathology and Parasitology, Sofia by subcuta neous inoculations of lxlO5 viable tumor cells. In the present experiments, 2xl04 viable tum or cells were inoculated s.c. in the interscapular field of hamsters. Such quantity of cells induced 100% transplantability and 100% mortality of hamsters according to our previous investigations (Tosh kova, 1995) .
Experimental animals
Two m onths old "Golden Siberian" hamsters from both sexes, weighing 80-100 g were used for the experiments. The animals were obtained from the animal house of the Institute of Microbiology, Bulgarian Academy of Sciences, Sofia. They were bred and grown under the standard conditions, ac cepted from the Bulgarian Veterinary Health Con trol Service.
Superoxide dismutase
The fungal strain H. lutea 103 from the Mycological Collection of the Institute of Microbiology, Bulgarian Academy of Sciences, Sofia, was used for the production of Cu/ZnSOD. Cultivation was perform ed in a 31 bioreactor ABR-09, developed and realized by the Central Laboratory for Bioin strum entation and Automatisation (CLBA) of the Bulgarian Academy of Sciences, Sofia. The biore 650 R. A. Toshkova < actor was equipped with a pH-monitoring system and an autom atic monitoring and controlling dis solved oxygen concentration (DO ) system. The ferm entation param eters were the same as de scribed earlier (Pashova et al., 1999) . The purified HLSOD with specific activity 3100 U/mg protein was prepared according to Dolashka-Angelova et al. (1999) . It is a water-soluble substance, a glycoprotein hom odimer with a molecular mass of approximately 30700 Da (unpubl data). Purity control of the enzyme was perform ed on 7.5% polyacrylamide gels, as described by Davis (1964) , and the gel stained for protein detection was com pared with a duplicate gel, stained for superoxide dismutase activity, as described by Misra and Fridovich (1977) . The SOD activity was m easured by the nitroblue tetrazolium (NBT) reduction m ethod of Beauchamp and Fri dovich (1971) . One unit of SOD activity was defined as the amount of SOD required for inhi bition of the reduction of NBT by 50% and was expressed as units per mg protein (U/mg pro tein). Sodium cyanide (2 mM) was used to distin guish between the cyanide-sensitive isoenzyme Cu/ZnSOD and the cyanide-resistant MnSOD. The C u/ZnSOD activity was obtained as total activity minus that in the presence of 2 mM so dium cyanide. The protein contents was esti mated after Lowry et al. (1951) , using crystalline bovine serum albumin as standard.
Doses and way o f application
For the examination of the optimal protective effect of HLSOD, 30 animals were separated in several experim ental groups, and were injected intraperitoneally (i.p.) with different doses before and after tum or transplantation (Fig. 1) 
Biometric parameters
Tumor trans p i ant ability (TT). Tumor transplantability (% ) was determ ined for each experim ental group at days 10, 12 and 15 as ratios between the num ber of tumor-bearing hamsters to the num ber of all hamsters in the group.
Inhibition o f tum or growth (ITG ).
The tum or size in mm (mean arithmetical value of two tum or diameters) was determ ined for each animal at days 10, 15, 20, 25 and 30 after tum or transplantation. Inhibition of tum or growth (ITG) was calculated according to the formula (Toshkova, 1995 M ortality (M). Mortality (% ) was followed at days 30, 35, 40 and 45 after tum or transplantation.
Immune status
The immune status of the experim ental animal injected by the optimal protective dose of 65 U HLSOD per animal, 2 times before and/or 5 times after tum or transplantation was examined by the following parameters:
Number, migration ability and phagocytic indices o f peritoneal macrophages were examined at days 7, 14 and 27 after tum or transplantation. The peri toneal cells were collected by washing of the peri toneal cavity with 20 ml cold H ank's balanced salt solution (pH 7.2). A fter two washings with RPM I 1640 medium (Sigma; Deisenhofen, Germ any) without supplements, the cells were adjusted to the necessary concentrations.
In vitro phagocytosis by peritoneal macrophages.
Macrophages in concentrations of lxlO 7 cells/ml in RPM I 1640 without supplements were allowed to adhere on glass lamellae for 2 h at 37 °C in humidified 5% C 0 2 atmosphere. A fter washing with phosphate-buffered saline (PBS), a suspen sion of killed Staphylococcus aureus Smith cells was added to a macrophage monolayer (the ratio between macrophages to bacteria was 1:20). The cells were allowed to interact 1 h under the same conditions, washed and stained according to Pappenheim (1911) . The phagocytic index (PI) was calculated according to the formula proposed by Ossada et al. (1982) :
PI(% )=(num ber of macrophages, containing bacterial cells per 200 counted macrophages) xlOO.
Migration o f peritoneal macrophages. Migration of macrophages in RPMI 1640 without the pres ence of antigen was examined by the m ethod de scribed by Leu et al. (1972) . Briefly, 6xl07/ml ma crophages in RPMI 1640 were introduced in hematocrit-siliconized glass capillaries (75/1 mm; for clinical laboratory use), one side stopped by bee vax. The capillaries were centrifuged at 4 °C for 5 min at 500 rpm, then they were cut at the level of the visible cell pools and fixed with silicon at the bottom of plastic petri dishes, containing RPMI 1640, supplemented by 10% fetal calf se rum (Sigma; Diesenhofen, Germany), L-glutamine and antibiotics. The migration fields were esti mated after 24 h incubation at 37 °C in humidified 5% C 0 2 atmosphere, using a projection apparatus and planimeter.
In vitro responsibility o f spleen lym phocytes to mitogens was estimated according to the method described by Masson and Guanzura (1990) . Briefly, the splenocytes were aseptically disinteg rated in RPMI 1640 without supplements. The ob tained cell suspensions were separated by gradient centrifugation on Ficoll-Paque (Pharmacia; U pp sala, Sweden). The cells from the interphase were collected, then washed 3 times and adjusted to lx l0 6/ml RPMI 1640, supplemented with L-glutamine, antibiotics and 20% fetal calf serum. The 100 ml/well lymphocyte suspensions were distrib uted in 96 plaque wells. Then, 50 ml phytohaemagglutinine from Phaseolus vulgaris (PHA; 25 mg/ml; Sigma; Germany) or 50 ml lipopolysaccharide from E.coli (LPS; 25 mg/ml; Sigma, Germany) were added per well. A fter incubation for 48 h at 37 °C in 5% C 0 2 atmosphere, the cells were pulsed with 1 mCi 3 H-thymidine per well and then reincubated for 18 h under the same conditions. The cells from each well were collected on nitro cellulose filters using a semiautomatic collector and distributed in scintillation bottles. The isotope uptake was determined with a scintillation counter (Intertechnique, France). Stimulation indices of lymphocytes (SI) were calculated according to the formula:
SI=number of Cpm of lymphocytes incubated with mitogen to Cpm of lymphocytes without mi togen.
Phagocytic indices o f PM Ns in the blood were estim ated at days 7, 14 and 27 after tumor trans plantation. They were determ ined according to the method of Vulchanov (1954) . Briefly, 0.10 ml pe ripheral blood and 0.05 ml of a 2% sodium citrate solution and 0.05 ml 2xl06 of a suspension of killed Staphylococcus aureus cells were allowed to interact in glass tubes for 1 h at 37 °C. Smears from each sample were prepared and stained by Pappenheim (1911) 
Statistical m ethods
Differences between the results of experimental groups were analyzed by the Student's T test. Data are presented as mean arithmetical values ±SD. P<0.05 was accepted statistically significant.
Results
According to the results, presented in Fig. 1 and 2, it could be established that a single dose of 65 U HLSOD per ham ster tended to be the most ef fective one during the treatm ent period (experi mental groups 1 and 2, see Fig. 1 ). For groups 1 and 2, treated by a single 65 U HLSOD dose per animal, on day 10 the tum or transplantability was only 20%, while animals treated by a single 125 U HLSOD dose per animal, was 75%, and for un treated TBH, 100% tum or transplantabilities were observed. On day 12, the experimental group 3 (125 U HLSOD/anim al) showed already 100% tu mor transplantability, while the experimental groups 1 and 2 (65 U HLSOD/animal) reached values of only 80%.
Furtherm ore, a decreased mortality (% ) at the early stage of tum or progression in hamsters treated by HLSOD was registered (Fig. 3) . At day 30 after tum or transplantation, the mortality for groups 1 and 2 (65 U HLSOD/animal) was 20% and for group 3 (125 U HLSOD/animal) 0%. For the control group it was 33%, and the latter increased to 100% within 5 days, while for groups 1 and 2 (65 U HLSOD/anim al) a mortality value of a only 40% was observed. T ra n s p la n ta tio n As dem onstrated by Fig. 4 , an inhibition of tu mor growth in the groups of HLSOD-treated tumor-bearing hamsters at the early stages of tumorgenesis (ITG=50% at day 15) was observed.
The results observed from the studies on m ortal ity, on tum or transplantability and inhibition of tu mor growth dem onstrate throughout that the ap plication of 65 U HLSOD/ham ster has an optimal protective effect for tumor-bearing hamsters. As next, observations of the effect of HLSOD at its optimal dose on the immune status of tum or-bear ing hamsters were performed.
I.p. application of a single 65 U dose of HLSOD per animal induced a 2 -4-fold increase of the peri toneal macrophage num ber in healthy animals (group 1) and a 1 -3-fold increase in TBH during the whole tested period (27 days) with a maximum at day 7 (10.31xl06 and 7.51xl06, respectively; number of macrophages of control group: 2.21xl06; Table I ). In the group of TBH without treatm ent, the number of macrophage was similar to that of the control group, with the exception around day 7, when a lower value (1.33xl06) was observed.
Futhermore, a suppression of the migration abil ity of peritoneal macrophages during tum or pro gression was registered (migration=1.60 mm2, 1.00 mm2 and 0.93 mm2; control group: 2.27 mm2 at days 7, 14 and 27, respectively; Table I ). HLSOD-treatm ent induced an increase of the macrophage migration ability of TBH, compared to the untreated animals with transplanted tumors (migration=1.91 mm2, 1.80 mm2 and 1.71 mm2, de termined at the same days of observation; HLSOD+T). H LSOD-treatem ent produced also a significant increase of macrophage migration in healthy control animals with a maximum at day 7 (migration=3.26 mm2, 3.12 mm2 and 2.25 mm2 at days 7, 14 and 27, respectively; Table I, HLSOD) .
Results of examinations of phagocytic abilities of peritoneal macrophages are presented in Ta ble I. Tumor progression induced a suppression of the macrophage phagocytic indices (PI= 38.51%, 28.25% and 26.56%, established at days 7, 14 and 27, control value 45.50%). HLSOD-treatm ent produced a stimulating effect on the macrophage phagocytic ability in TBH and in healthy animals at the 7th day (PI=53.53% and 71.21%, respec tively). Later, the PI values of both groups grad ually decreased, but after passing day 14, the H LSO D -treated TBH showed increasing PI val ues again (T and HLSOD+T).
Phagocytic indices of PMNs in peripheral blood of tum or-bearing hamsters were decreased during the whole period of the observation (PI= 38.50%, 24.53% and 20.00% at days 7, 14 and 27, respec tively, control value: 45.50%; Table I : T and Con trol). In the group of HLSO D -treated TBH, the phagocytic ability of PMNs was higher compared to the untreated animals with tumors (PI=54.51%, 41.51% and 64.00% at days 7, 14 and 27, respec tively, HLSOD+T). The highest phagocytic index (71.55%) was found for the group of HLSODtreated healthy animals at day 7 of observation (HLSOD).
Results of the investigations on the in vitro re sponsibility of spleen lymphocytes to mitogens are presented on Table I . It dem onstrated that tumor progression and/or HLSOD application did not produce any significant changes in lymphocyte stimulating indices (SI) in the presence of phytohaemagglutinine (PHA). The SI of proliferative responses of spleen lymphocytes to E. coli LPS in the group of TBH were insignificantly impaired till day 14 com pared to the controls (SI=1.70 and 1.74, at days 7 and 14 respectively, values for con trol animals: 1.43; Table I ; T and Control), but fol lowed by a 100% decrease at day 27. HLSOD treatm ent induced in TBH a marked increase of B lymphocyte mitogen reactivity to LPS with a maximum at day 7 of the investigation (SI=3.17 and 2.15 at days 7 and 14, respectively; HLSOD+T), followed by a 3-fold decrease at day 27 compared to the control. HLSOD increased also significantly B lymphocyte mitogen reactivity in healthy animals (SI=2.51 and 3.39 at days 7 and 14; HLSOD).
Discussion
The obtained experim ental data dem onstrate the protective effect of H. lutea SOD on the sur vivability of hamsters with transplanted myeloid Graffi tumors, as expressed by (i) decreased tumor transplantability, (ii) inhibition of tum or growth and (iii) reduced mortality percentage. Similarly Oberley and B uettner (1979) established elonga tion of survival time of experimental animals with Ehrlich ascites and Sarcoma 180 tum or after intra venous and intram uscular injection of Cu/ZnSOD. This protective effect can be partly explained by the tem porary immunostimulating and immunor estoring action of the preparation on the phago cytic activity of macrophages and PMNs at the be ginning stage of tum or progression ( 7 -14th day) as well as by the stimulating effect on the prolifer ating ability of B lymphocytes.
The transitory character of immunorestorating and protective effects of the preparation can be explained by the intervention of the tum or immu nosuppression during tum or progression (Finke et al., 1999; Alexandroff et al., 1998). Reactive oxy gen species (ROS) and antioxidants were shown to influence the development of malignant diseases. Kogawa et al. (1999) reported that ROS enhanced inhibition of tum or cell metastasis of mouse Meth A sarcoma and Lewis lung carcinoma after treat m ent with Cu/ZnSOD and adriamycin.
Increased expression of MnSOD has been de tected in several classes of human and experim en tal tum ors and appears to correlate with poorer prognosis in human neuroepithelial, ovarian and cervical tumors. These observations suggest that M nSOD provides a mechanism for counteracting the intracellular oxidative processes that impairs cell growth and viability in the context of growth factor withdrawal which may promote tumor-cell survival in vivo under conditions unfavourable to cell growth (Palazzotti et al., 1999 In conclusion, i.p. application of Cu/ZnSOD from Humicola lutea induces a protective and imm unorestoring effect in hamsters with progressing myeloid Graffi tumor. Three possible mechanisms for this action can be hypothesized:
• Cu/ZnSOD from Humicola lutea improves the oxidant-antioxidant balance in peritoneal ma crophages and PMNs resulting in decreased toxic changes and increased phagocytic abilities of these cells.
• Cu/ZnSOD from Humicola lutea increases the levels of H 20 2 from radicals which supposedly can not be detoxified by most cancer cell types ).
• The presence of polysaccharide chains in the HLSOD molecule probably contribute to the immunostimulating action of the preparation.
